Clarivate (NYSE:CLVT) Issues Quarterly Earnings Results

Clarivate (NYSE:CLVT) released its quarterly earnings results on Wednesday. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.03, FiscalAI reports. The business had revenue of $481.60 million for the quarter, compared to the consensus estimate of $566.77 million. Clarivate had a negative net margin of 13.84% and a positive return on equity of 9.15%. The company’s quarterly revenue was down 22.7% on a year-over-year basis. During the same period last year, the firm earned $0.18 earnings per share.

Clarivate Price Performance

Shares of CLVT traded up $0.08 during trading hours on Wednesday, reaching $2.17. 4,787,580 shares of the stock traded hands, compared to its average volume of 6,008,222. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.93. Clarivate has a 52-week low of $1.42 and a 52-week high of $3.87. The company’s 50-day moving average price is $1.81 and its two-hundred day moving average price is $2.22. The company has a market cap of $1.39 billion, a P/E ratio of -4.16 and a beta of 1.38.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CLVT. Barclays reduced their price objective on Clarivate from $2.50 to $2.00 and set an “underweight” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a report on Monday, September 21st. William Blair cut Clarivate to a “market perform” rating in a research report on Thursday, October 15th. Morgan Stanley began coverage on Clarivate in a research note on Friday, October 30th. They issued an “underweight” rating and a $1.50 price objective on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of Clarivate from $2.90 to $2.60 and set a “neutral” rating for the company in a report on Thursday, July 30th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Clarivate currently has an average rating of “Reduce” and an average target price of $2.77.

Insider Transactions at Clarivate

In other Clarivate news, Director Kenneth Cornick purchased 250,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $1.85 per share, for a total transaction of $462,500.00. Following the purchase, the director owned 2,000,000 shares of the company’s stock, valued at approximately $3,700,000. This represents a 14.29% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 22.88% of the company’s stock.

Clarivate News Roundup

Here are the key news stories impacting Clarivate this week:

• Positive Sentiment: Clarivate said recurring organic revenue growth improved and its Intellectual Property segment returned to positive annual contract value growth. It also reported adjusted EPS of $0.21, ahead of estimates, and expects 2027 free cash flow to grow 10%–15% following the Life Sciences & Healthcare divestiture. Clarivate Q3 results 2027 free cash flow outlook
• Positive Sentiment: A strategic alliance with Microsoft will bring Clarivate’s trademark data into Microsoft Copilot through IPOne, offering a potential channel to expand the reach of its data and AI-enabled services. Microsoft alliance announcement
• Neutral Sentiment: Clarivate launched cash tender offers for up to $500 million of its 2028 and 2029 notes. The move could help manage debt, but it also uses cash; the ultimate impact depends on how much debt is repurchased and the transaction terms. Debt tender offer announcement
• Negative Sentiment: Q3 revenue was $481.6 million, well below the roughly $567 million consensus estimate, and declined 22.7% year over year. The revenue miss outweighed the EPS beat and was reported to have driven a sharp share decline, keeping questions about growth and the effects of the portfolio changes in focus. Q3 revenue miss and share reaction

About Clarivate

Clarivate Plc (NYSE:CLVT) provides analytics, data, and workflow solutions to organizations in academia, government, research, life sciences, and intellectual property. Its offerings are designed to help customers evaluate research, manage information, accelerate innovation, and support strategic decision-making.

The company’s products include Web of Science research databases and citation analytics, InCites research evaluation tools, Derwent innovation and patent intelligence services, and Cortellis life sciences and drug-development information.